Celularity Inc. (CELU) Stock Analysis
A live, multi-source view of Celularity Inc. (CELU): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Celularity Inc.
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc.
Sector: Healthcare · Industry: Biotechnology · United States · 115 employees · celularity.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Celularity Inc. (CELU) had a market capitalization of $48.6M (forward -2.9) and a beta of 0.80; the shares traded in a 52-week range of $0.56 – $2.55 (-13.3% over the year).
- Market cap
- $48.6M
- Enterprise value
- $117.5M
- Forward P/E
- -2.9
- EPS (trailing)
- $-3.30
- EPS (forward)
- $-0.57
- Payout ratio
- 0.0%
- 52-week range
- $0.56 – $2.55
- 52-week change
- -13.3%
- Beta
- 0.80
- Average volume
- 4.0M
- Shares outstanding
- 28.9M
- Short % of float
- 6.06%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Celularity Inc. (CELU) last closed at $1.44 (the last completed close before that scan).
Technicals at the scan: RSI 57 (neutral territory), price +20.0% versus its 20-day average, 20-day versus 50-day average spread +31.9%, MACD histogram 0.03.
Sentiment inputs: StockTwits 78% bullish.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for CELU in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
CELU has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Celularity Inc. (CELU) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell CELU.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.